Topical Voltaren in Otitis Externa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00523120
Recruitment Status : Terminated
First Posted : August 30, 2007
Last Update Posted : April 20, 2016
Information provided by (Responsible Party):
victor kizhner, Sieff Medical Center

Brief Summary:
Voltaren being a Non-steroidal anti-inflammatory drug (NSAID) drug may be used as a single drug therapy in otitis externa being both therapeutic and analgesic thus reducing consumption of oral analgesia.

Condition or disease Intervention/treatment Phase
Otitis Externa Drug: diclofenac sodium Drug: dexotc Phase 2

Detailed Description:
anticipated advantages are: reduction of inflammation and edema, no fungal overpopulation- when steroids are employed, contains boric acid as an ingredient, high safety profile, can be switched to antibiotic therapy later, can be used in conjunction wit steroids

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Topical Voltaren as an Alternative Treatment for Otitis Externa
Study Start Date : September 2008
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1
voltaren ophta
Drug: diclofenac sodium
topical solution used in ear 5 drops 8 3/day
Other Name: voltaren ophta

Active Comparator: 2
Drug: dexotc
aural drops
Other Name: dexotic

Primary Outcome Measures :
  1. reducing oral analagestic use [ Time Frame: 1 week ]

Secondary Outcome Measures :
  1. adding an alternative treatment for otitis externa [ Time Frame: 1 week ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Adults having otitis externa as single diagnosis mild to moderate

Exclusion Criteria:

  • Diabetes
  • Children
  • Pregnant women
  • Immune compromise
  • Starting other treatment
  • Moderate to severe otitis externa

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00523120

Sieff Medical Center
Safed, Israel, 13100
Sponsors and Collaborators
Sieff Medical Center
Principal Investigator: victor kizhner, m.d. Sieff Medical Center, Safed, ISRAEL

Additional Information:
Responsible Party: victor kizhner, Victor Kizhner MD, Sieff Medical Center Identifier: NCT00523120     History of Changes
Other Study ID Numbers: HP 7-264S
First Posted: August 30, 2007    Key Record Dates
Last Update Posted: April 20, 2016
Last Verified: April 2016

Additional relevant MeSH terms:
Otitis Externa
Ear Diseases
Otorhinolaryngologic Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action